Document is current
Any future updates will be listed below
-
Authors
Wang, Qian
Guo, Yicheng https://orcid.org/0000-0001-5357-660X
Iketani, Sho https://orcid.org/0000-0002-3733-9556
Nair, Manoj S. https://orcid.org/0000-0002-5994-3957
Li, Zhiteng
Mohri, Hiroshi https://orcid.org/0000-0003-3101-7625
Wang, Maple
Yu, Jian
Bowen, Anthony D. https://orcid.org/0000-0003-1064-8372
Chang, Jennifer Y.
Shah, Jayesh G.
Nguyen, Nadia
Chen, Zhiwei https://orcid.org/0000-0002-4511-2888
Meyers, Kathrine
Yin, Michael T.
Sobieszczyk, Magdalena E.
Sheng, Zizhang
Huang, Yaoxing https://orcid.org/0000-0001-6270-1644
Liu, Lihong https://orcid.org/0000-0003-3128-8513
Ho, David D. https://orcid.org/0000-0003-1627-149X
- License Information
-
More Information
Article History
Received: 26 May 2022
Accepted: 30 June 2022
First Online: 5 July 2022
Competing interests
: S.I, J.Y., Y.H., L.L. and D.D.H. are inventors on patent applications (WO2021236998) or provisional patent applications (63/271,627) filed by Columbia University for several SARS-CoV-2 neutralizing antibodies described in this paper. Both sets of applications are under review. D.D.H. is a cofounder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences and board director for Vicarious Surgical.
